Mazzara Philip

General Counsel at Astera Labs sold 14,076 shares ($3.3M) across 18 transactions on 2026-05-18 at blended avg $231.78 vs current $287.48

Philip Mazzara, General Counsel and Secretary of Astera Labs, executed 18 separate sales totaling 14,076 shares for $3,262,539.72 on a single date (2026-05-18), reducing his holdings by 11.9% from 118,215 to 104,139 shares at an average price of $231.78. The current stock price of $287.48 is now +9.4% above the 52-week high, and the stock has surged +63.5% in 30 days and +116.8% in 90 days since these sales. His prior 5 trades at ALAB (all sells on 2026-04-01) showed 30-day returns ranging from +83.7% to +90.6% and 90-day returns from +121.4% to +129.7%, with 0 of 5 classified as well-timed at the 90-day mark—a notable pattern of selling into sustained appreciation. The scale of this single-day liquidation (18 tranches, $3.3M, spanning prices from $235.36 down to $221.01) suggests a systematic execution rather than opportunistic trading, and the consistent underperformance of his prior timing at this ticker contrasts sharply with the company's fundamentals: revenue growth of +115.1% year-over-year and net income of $80,310,000.00 on quarterly revenue of $308,361,000.00.

General Counsel Mazzara sells 10.0K shares at $107.77 avg; stock now -53.5% from 52-week high of $251.88

Philip Mazzara, General Counsel and Secretary of Astera Labs, executed 5 separate sales totaling 10,000 shares for $1,077,662.85 on 2026-04-01 at an average price of $107.77. The current price is $117.14, representing a 30-day return of +6.7%, but the stock remains -53.5% from its 52-week high of $251.88 and -34.8% over the past 90 days. Across his cross-ticker track record, Mazzara's 20 prior sells have averaged -34.0% 90-day returns with a 100.00% well-timed rate, suggesting his sales historically precede price declines; however, this current transaction occurred well after the stock's peak, and his same-ticker history at ALAB shows 5 recent sells from 2026-03-02 that have underperformed (ranging -6.6% to -11.6% at 30 days). The transaction reduces his ALAB holdings by 7.8% to 118,084 shares, a material but not complete exit. Against fundamentals of $230.6M quarterly revenue, +115.1% annual growth, and a P/E of 39.71, this sale does not appear to signal a fundamental loss of conviction, but rather reflects liquidity management as the stock has already sustained a sharp 90-day decline from peak levels.

General Counsel Mazzara sells 10,000 shares at $117.47 avg; stock down 25.4% in 30/90 days, down 54.8% from 52-week high

Philip Mazzara (General Counsel and Secretary) executed 8 separate sales totaling 10,000 shares for $1,174,740.60 at a blended average price of $117.47 on 2026-03-02, reducing his holdings by 7.2%. The sales occur as ALAB stock has declined sharply: -25.4% over the past 30 and 90 days, and -54.8% from its 52-week high of $251.88. Mazzara's cross-ticker track record shows a 100.00% well-timed 90-day rate across 20 prior sells with an average 90-day return of -11.2%, indicating his prior sales have generally preceded or occurred during downturns. However, his 5 most recent same-ticker trades at ALAB (all on 2026-02-17, just 13 days before this filing) have outcomes not yet measurable, so timing accuracy cannot be assessed at this specific ticker. The company's fundamentals remain solid—annual revenue growth of +115.1%, net income of $91,114,000.00, and a market cap of $19,365,304,006.31—suggesting the recent stock decline is not driven by earnings deterioration but rather reflects broader market or sector pressure.

Astera Labs GC/Secretary Mazzara sold 4,849 shares at blended avg $123.80 on 2026-02-17 ($600.3K); current price $132.62, stock -27.8% in 30 days.

Mazzara executed 5 separate sales totaling 4,849 shares for $600,327.61 at an average price of $123.80, reducing his post-transaction holdings to 138,084 shares (-3.4% reduction). The stock has since risen to $132.62 (current price), representing an 8.2 cent upside from the transaction's blended average, yet the broader context is concerning: the 30-day return is -27.8%, placing the transaction within a severe downturn that contradicts the current price snapshot. His cross-ticker track record shows a 100% well-timed sell rate with an average 90-day return of -11.1%, suggesting strong historical timing acumen. However, at ALAB specifically, his prior five sales from 2026-01-02 have all shown negative 30-day returns (-12.8% to -15.9%), with no measurable 90-day data yet, indicating a consistent pattern of selling into subsequent declines at this ticker. The company's fundamentals remain mixed: while latest-quarter net income of $91.1M is substantial and annual revenue growth reached +242.2%, the company remained unprofitable on a full-year basis with a P/E of 112.39 and stock trading -47.4% from its 52-week high, signaling a high-valuation multiple now contracted.

General Counsel Mazzara sells 10,000 shares at $178.41 avg (blended) on 2026-01-02; stock now -36.1% from 52-week high.

Philip Mazzara, General Counsel and Secretary at Astera Labs, executed 9 separate sales totaling 10,000 shares for $1,784,071.01 on 2026-01-02, reducing his holdings from 147.0K to 137.0K shares (-6.8%). The trades across a range of prices ($172.65 to $182.12, blended average $178.41) occurred as the stock trades at $161.01, down 36.1% from its 52-week high of $251.88 and down 26.6% over the past 90 days. Mazzara's prior sales at ALAB (5 trades on 2025-10-01 and 2025-11-17) have shown consistent post-execution declines of 2.3% to 4.6% at the 30-day mark, with the measurable 90-day outcome from October showing -12.7%, suggesting a pattern of selling before downward pressure. The company's fundamentals show significant revenue growth (+242.2% annually) but elevated P/E of 136.45 and a full fiscal year of negative net income despite recent quarterly profitability ($91.1M net income in latest quarter), indicating near-term execution risks in a high-growth but historically unprofitable business.

Mazzara (General Counsel) sold 4,620 shares for $668,476.57 at blended avg $144.69; stock now $142.01, down 43.6% from 52-week high.

Philip Mazzara, General Counsel and Secretary, executed 4 separate sales totaling 4,620 shares (4.6K shares) for $668,476.57 at an average price of $144.69 on 2025-11-17, reducing his holdings by 3.0% to 147,040 shares. The transaction occurred as ALAB stock trades $142.01, down 9.2% over the past 30 days and 20.0% over 90 days from the sale date—a notable decline from the transaction prices. His prior 5 trades at ALAB (all on 2025-10-01) showed modest negative 30-day returns, with 90-day outcomes not yet measurable; across his cross-ticker history, prior sales posted a 50% well-timed rate at the 90-day mark. The company reported strong quarterly revenue of $230,575,000.00 and net income of $91,114,000.00, though it remains unprofitable on an annual basis with a 120.35 P/E, suggesting the market prices in significant future growth expectations amid current valuation pressures.

Astera Labs General Counsel sells 10,000 shares for $1.9M; price now $200.74, 20.3% below 52-week high of $251.88

Philip Mazzara, General Counsel and Secretary, executed 9 separate sales totaling 10,000 shares (10.0K shares) for $1,921,572.16 on 2025-10-01 at a blended average price of $192.16, reducing his holdings from 161.6K to 151.6K shares (-6.2%). The stock currently trades at $200.74, up 13.7% over 30 days and +121.1% over 90 days, suggesting Mazzara's sales occurred near an inflection point before continued strength. His prior 5 trades at ALAB (all August 28 sells) showed 30-day gains of +3.8% to +8.3%, indicating a pattern of selling into temporary softness. The company's fundamentals are mixed: recent quarter revenue of $191,925,000.00 with net income of $51,219,000.00, but annual growth of +242.2% masks that the full fiscal year remained unprofitable, and a P/E of 334.57 reflects substantial premium valuation. The sale size and timing, combined with the stock's subsequent rally and the company's elevated valuation multiples, warrant observation of whether this represents routine diversification or a signal of reduced conviction at these price levels.

General Counsel Mazzara sold 10,000 shares at blended avg $188.70 on 2025-08-28, reducing ALAB stake by 5.8%; stock +32.9% in 30d, now -10.0% from 52-week high.

Philip Mazzara, General Counsel and Secretary of Astera Labs, executed 7 separate sales totaling 10,000 (10.0K shares) for $1,886,956.17 ($1.9M) on 2025-08-28 at a blended average price of $188.70, leaving him with 161,573 shares (161.6K shares) post-transaction. The current stock price of $174.24 is -10.0% from the 52-week high of $193.64, and notably the stock has gained +32.9% over the past 30 days and +83.0% over the past 90 days—suggesting the timing of this sale falls within a period of significant recent appreciation. His prior trades at ALAB show a pattern of 0 of 3 measurable prior sells being well-timed at the 90-day mark (all three resulted in positive 90-day returns post-sale, ranging from +10.4% to +111.1%), indicating the stock has consistently risen after his prior exits. This large discretionary sale by a senior legal officer—representing -5.8% of his pre-transaction holdings—combined with the historically consistent post-sale rallies in ALAB stock and the company's extremely elevated P/E of 290.40, warrants close monitoring of fundamental conditions and insider intent.

General Counsel Mazzara sells 7,237 ALAB shares for $1,328,064.80; stock up 82.9% in 90 days post-May sales, signaling poor timing at ALAB.

Philip Mazzara, General Counsel and Secretary, executed 2 separate sales totaling 7,237 shares for $1,328,064.80 (blended average $183.51 per share) on 2025-08-18, reducing his holdings by 4.0% to 171,573 shares. The sale occurred with the stock trading at $183.51, only 5.3% below the 52-week high of $193.64. Mazzara's prior 5 trades at ALAB, all sells, have shown unfavorable timing: each subsequent 90-day period produced significant positive returns (ranging from +6.3% to +111.1%), indicating he sold before substantial rallies. His cross-ticker track record shows a 5.00% well-timed rate (lower than desirable), though his 30-day returns average +6.5%. The current stock is up 82.9% over 90 days and +41.5% over 30 days, suggesting his May 2025 exits preceded a sustained rally. With the company posting 242.2% annual revenue growth, $191.9M in latest quarterly revenue, and $51.2M net income, despite a 287.42 P/E multiple and negative full-year net income prior, continued weakness in insider timing at this ticker merits observation of subsequent filings.

General Counsel Mazzara sells 28,809 shares across 4 transactions for $2,598,585.95; prior ALAB sales show consistent 18-20% negative 30-day returns.

Philip Mazzara, General Counsel and Secretary, executed 4 separate sales totaling 28,809 shares (28.8K shares) for $2,598,585.95 at a blended average price of $90.20, reducing his holdings by 15.1% from 191,405 shares to 162,596 shares. His prior 5 transactions at ALAB (all conducted on 2025-02-20) each posted negative 30-day returns ranging from -17.1% to -20.3%, suggesting a consistent pattern of selling before subsequent declines at this ticker. His cross-ticker track record shows a 90d well-timed rate of 6.67% across 20 prior sells, indicating below-average timing precision on a cross-ticker basis. The current stock price of $94.46 sits 35.2% below the 52-week high of $145.81, though it is 60.2% higher than 30 days ago; the company trades at an extreme P/E of 377.84 despite full-year unprofitability, warranting attention to whether the recent 30-day surge masks execution risk or fundamental instability.